MinervaX Overview
- Year Founded
-
2009
- Status
-
Private
- Employees
-
50
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$57.3M
- Investors
-
21
MinervaX General Information
Description
Developer of maternal vaccines designed for the prevention of adverse pregnancy outcomes and life-threatening infections caused by group B streptococcus. The company's vaccines specialize in the research and development of drugs that utilize a particular fusion protein that elicits protective immunity against a range of clinically relevant streptococci strains, enabling medical professionals to prevent newborn babies from contracting bacterial infections.
Contact Information
Website
www.minervax.comCorporate Office
- Nordre Fasanvej 215
- 2200 Frederiksberg
- Denmark
Corporate Office
- Nordre Fasanvej 215
- 2200 Frederiksberg
- Denmark
MinervaX Timeline
MinervaX Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 13. Later Stage VC | 11-Oct-2023 | $57.3M | Completed | Clinical Trials - Phase 3 | ||
| 12. Later Stage VC | 13-Dec-2022 | Completed | Clinical Trials - Phase 2 | |||
| 11. Later Stage VC (Series B) | 15-Dec-2020 | Completed | Clinical Trials - Phase 2 | |||
| 10. Secondary Transaction - Private | Completed | Clinical Trials - Phase 1 | ||||
| 9. Later Stage VC | 21-Jan-2019 | Completed | Clinical Trials - Phase 1 | |||
| 8. Grant | 19-Sep-2016 | Completed | Clinical Trials - Phase 1 | |||
| 7. Later Stage VC | 15-Feb-2016 | Completed | Clinical Trials - Phase 1 | |||
| 6. Grant | 28-Oct-2015 | Completed | Clinical Trials - Phase 1 | |||
| 5. Debt - General | $4.79M | Completed | Clinical Trials - Phase 1 | |||
| 4. Later Stage VC | 08-Jan-2014 | $4.04M | $4.79M | Completed | Clinical Trials - Phase 1 |
MinervaX Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | ||||||||
| Ordinary Shares | ||||||||
| Ordinary Shares | ||||||||
| C Shares | 1,683,836 | $0.142233 | $3.98 | $3.98 | 1x | $3.98 | 6.72% | |
| Series B | 106,822 | $0.142233 | $5.69 | $5.69 | 1x | $5.69 | 0.43% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
MinervaX Comparisons
Industry
Financing
Details
MinervaX Competitors (48)
One of MinervaX’s 48 competitors is Immunethep, a Venture Capital-Backed company based in Cantanhede, Portugal.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Immunethep | Venture Capital-Backed | Cantanhede, Portugal | ||||
| Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA | ||||
| Virometix | Venture Capital-Backed | Schlieren, Switzerland | ||||
| Anaveon | Venture Capital-Backed | Basel, Switzerland | ||||
| Light Chain Bioscience | Formerly PE-Backed | Geneva, Switzerland |
MinervaX Patents
MinervaX Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4837587-A1 | Immunogenic fusion protein | Pending | 06-May-2025 | ||
| WO-2026234068-A1 | Immunogenic fusion protein | Pending | 06-May-2025 | ||
| EP-4825390-A1 | Method for producing a recombinant fusion protein | Pending | 17-Apr-2025 | ||
| WO-2026220014-A1 | Method for producing a recombinant fusion protein | Pending | 17-Apr-2025 | ||
| EP-4825389-A1 | Method for purifying a recombinant fusion protein | Pending | 17-Apr-2025 | C07K14/315 |
MinervaX Signals
MinervaX Investors (21)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| EQT Life Sciences | Venture Capital | Minority | ||
| Kinled Holding | Family Office | |||
| Novo Holdings | Venture Capital | Minority | ||
| OrbiMed | Growth/Expansion | Minority | ||
| Pureos Bioventures | Venture Capital | Minority |
MinervaX FAQs
-
When was MinervaX founded?
MinervaX was founded in 2009.
-
Where is MinervaX headquartered?
MinervaX is headquartered in Frederiksberg, Denmark.
-
What is the size of MinervaX?
MinervaX has 50 total employees.
-
What industry is MinervaX in?
MinervaX’s primary industry is Drug Discovery.
-
Is MinervaX a private or public company?
MinervaX is a Private company.
-
What is the current valuation of MinervaX?
The current valuation of MinervaX is .
-
What is MinervaX’s current revenue?
The current revenue for MinervaX is .
-
How much funding has MinervaX raised over time?
MinervaX has raised $203M.
-
Who are MinervaX’s investors?
EQT Life Sciences, Kinled Holding, Novo Holdings, OrbiMed, and Pureos Bioventures are 5 of 21 investors who have invested in MinervaX.
-
Who are MinervaX’s competitors?
Immunethep, Inovio Pharmaceuticals, Virometix, Anaveon, and Light Chain Bioscience are some of the 48 competitors of MinervaX.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process